Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke

ClinicalTrials.gov ID: NCT03763929

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03763929. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Efficacy and Safety of Trans Sodium Crocetinate (TSC) Administered Onboard Emergency Vehicles for Treatment of Suspected Stroke: PHAST-TSC

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the potential efficacy and safety of TSC as early treatment for both ischemic and hemorrhagic stroke when administered while subject is in ambulance being transported to hospital.

Study identification

NCT ID: NCT03763929
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Enrollment: 6 participants

Conditions and interventions

Conditions

Stroke, Acute

Interventions

Trans-Sodium Crocetinate Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 40 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 22, 2019 (Actual)
Primary completion: Oct 19, 2020 (Actual)
Completion: Oct 19, 2020 (Actual)
Last update posted: Jun 18, 2021

2019 – 2020

United States locations

U.S. sites: 2
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
University of California, Los Angeles	Los Angeles	California	90095	—
University of Virginia	Charlottesville	Virginia	22908	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03763929, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 18, 2021 · Synced Nov 12, 2026